Skip to main content
52°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Natera, Inc.
< Previous
1
2
3
Next >
Natera to Participate in Upcoming Investor Conferences
November 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its Third Quarter 2024 Results on November 12, 2024
November 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Renasight Data at ASN Kidney Week 2024
October 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
September 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
September 16, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
June 17, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
May 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its First Quarter 2024 Results on May 9
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
April 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.